{"filings":[{"id":1140479,"accession_number":"0001477932-26-003932","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2026-06-18T21:00:40+00:00","items":["3.02"],"status":"ready","headline":"VolitionRx issues 545,591 shares to Lind Global to satisfy $833,332 in debt payments","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On June 17, 2026, issued 333,332 shares to Lind for $416,666 payment obligation.","On May 19, 2026, issued 212,259 shares to Lind for another $416,666 payment obligation.","Shares issued under existing convertible note; exemption claimed under Section 3(a)(9) and 4(a)(2).","No commissions paid; offering not a public offering; no general solicitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":954208,"accession_number":"0001477932-26-003740","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2026-06-09T23:04:13+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"VolitionRx prices $4.6M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 2,960,000 shares at $1.55 each plus half-warrant; gross proceeds ~$4.6M.","Net proceeds ~$4.1M after fees; additional $2.3M possible if warrants fully exercised.","Use of proceeds: R&D, clinical studies, commercialization, working capital, repaying secured convertible notes.","Maxim Group LLC acted as sole placement agent; offering closed June 9, 2026.","Warrants exercisable at $1.55 per share immediately, expire in 5 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":611518,"accession_number":"0001477932-26-003416","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2026-05-22T21:00:21+00:00","items":["1.01"],"status":"ready","headline":"VolitionRx breaches market cap covenant on notes; obtains waiver with 10% penalty and conversion adjustment","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Breached minimum market capitalization covenant on $7.5M (2025) and $2.4M (2026) convertible notes to Lind.","Lind waived rights to accelerate or foreclose; Company must pay additional 10% of outstanding principal.","Conversion price may be lowered to 90% of avg three lowest VWAPs over 20 trading days, subject to 4.99% cap.","Waiver executed May 21, 2026; avoids immediate default but increases future dilution risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":472120,"accession_number":"0001477932-26-003241","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2026-05-15T20:45:22+00:00","items":["5.02"],"status":"ready","headline":"Director Mickie Henshall not standing for re-election; board reduces to 7 directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mickie Henshall notified board she will not stand for re-election at the 2026 Annual Meeting.","No disagreement with the company on operations, policies, or practices.","Board size reduced from eight to seven directors, effective before the 2026 Annual Meeting.","Ms. Henshall had served on the board since August 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":443040,"accession_number":"0001477932-26-003126","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2026-05-14T20:18:53+00:00","items":["2.02","9.01"],"status":"ready","headline":"VolitionRx Q1 2026 revenue $1.0M; $5M milestone potential from feline lymphoma test","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $1.0M in Q1 2026 vs $0.2M in Q1 2025; operating loss decreased 3% YoY.","Net cash used in operations was $5.3M; raised $5.4M from ATM equity and $1.9M from convertible note.","Received $1M in non-dilutive Walloon Region funding; ~$0.9M more expected over 12 months.","Feline lymphoma assay manuscript submitted for peer review; expected to unlock $5M milestone payment.","Discussions ongoing with >12 diagnostic companies for licensing; Nu.Q Lung Cancer reimbursement in France progressing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":985076.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99883,"accession_number":"0001477932-26-002619","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"VolitionRx completes 1-for-20 reverse stock split effective April 28, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse split at special meeting March 31, 2026; Board set ratio at 1:20.","Certificate of Amendment filed with Delaware on April 27, 2026, effective 12:01 a.m. ET April 28, 2026.","Reverse split applies to all outstanding common shares; fractional shares treated per amendment.","Common stock continues trading on NYSE American under ticker VNRX."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99882,"accession_number":"0001477932-26-002472","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"NYSE American accepts VolitionRx compliance plan; shares continue trading until Aug 2027 review","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received non-compliance notice on Feb 6, 2026 for stockholders' equity deficiency (below $2M threshold).","Compliance plan submitted by March 8, 2026; accepted by NYSE American on April 22, 2026.","Company has until August 6, 2027 to regain compliance; subject to periodic NYSE American review.","If plan progress insufficient or compliance not met by deadline, delisting proceedings may be initiated.","No immediate impact on listing; common stock continues trading under symbol VNRX on NYSE American."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99881,"accession_number":"0001477932-26-002373","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["8.01","5.07"],"status":"ready","headline":"VolitionRx board approves 1-for-20 reverse stock split effective April 28, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio set at 1-for-20, effective 12:01 a.m. ET on April 28, 2026.","No fractional shares; holders receive one whole share for any fractional interest.","Proportional adjustments to outstanding warrants, options, awards, and convertible notes.","Split follows shareholder approval at March 31, 2026 special meeting; tied to Lind Global financings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99880,"accession_number":"0001477932-26-001940","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"VolitionRx shareholders approve share issuance to Lind Global and reverse stock split authorization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1 (issuance >20% to Lind Global): 44.15M for, 14.10M against, 1.11M abstain, 21.15M broker non-votes approved.","Proposal 2 (reverse split authorization): 62.84M for, 16.45M against, 1.22M abstain; board may choose ratio 1:5 to 1:20.","Record date Feb 9, 2026: 135.57M shares outstanding; 80.51M shares present at special meeting on March 31, 2026.","No other matters were presented for stockholder action at the special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116158,"accession_number":"0001477932-26-001830","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VolitionRx FY2025 revenue up 40% to $1.7M; net loss down 14%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year revenue $1.7M (+40% YoY); Q4 revenue growth 133% vs prior year.","Operating expenses down $4.8M (17%); net cash used in ops $19.7M (-24%).","Received first order for Nu.Q Cancer assays for lung cancer clinical certification.","Nu.Q NETs assay included in French government-backed sepsis study (~$7.3M).","Subsequent to year end: raised $5.4M ATM equity, $1.9M convertible note, $1.0M non-dilutive."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":985076.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116157,"accession_number":"0001477932-26-000955","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"VolitionRx issues 6.4M shares to Lind Global to satisfy $1.42M debt payments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Feb 17, 2026: issued 1,956,178 shares to Lind Global for $416,666 payment.","Jan 29, 2026: issued 2,569,753 shares for $583,334 payment.","Jan 16, 2026: issued 1,893,936 shares for $416,666 payment.","Shares issued under Section 4(a)(2) / Rule 506 exemption; no commissions or public offering.","Also notes Sep 2025 private placement: 483,870 shares + warrants at $0.62/unit for $300,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116156,"accession_number":"0001477932-26-000714","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"VolitionRx receives NYSE American non-compliance notice for stockholders' equity; must submit plan by March 8, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received NYSE American notice on Feb 6, 2026 for failing $2M, $4M, $6M stockholders' equity thresholds due to sustained losses.","Must submit compliance plan by March 8, 2026; deadline to regain compliance is August 6, 2027.","Stock will trade under VNRX with \".BC\" designation indicating \"below compliance.\"","If plan not submitted or accepted, NYSE American will commence delisting proceedings.","No immediate impact on listing or business operations; company intends to submit a plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116155,"accession_number":"0001477932-26-000107","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"VolitionRx secures $2.0M funding from Lind Global with convertible note and warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Gross proceeds $2M; issues $2.4M senior secured convertible note and 7,000,350 warrants at $0.5714/share.","Note has 18 monthly payments of $133,333 beginning 6 months after issuance; no interest accrues.","Lind may increase up to 2 monthly payments to $1M each on notice.","This is additional to existing $7.5M note from May 2025 with Lind.","Company must file resale registration statement within 30 days of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132608,"accession_number":"0001477932-25-008932","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"VolitionRx subsidiary CEO Dr. Butera to depart Jan 31, 2026; position eliminated","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Volition Veterinary CEO Dr. Salvatore Thomas Butera given termination notice, effective Jan 31, 2026.","CEO position eliminated as part of ongoing cost-realignment efforts; duties redistributed.","Dr. Butera expected to stay as part-time consultant post-termination under agreed terms.","Departure not due to any disagreement with company on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132607,"accession_number":"0001477932-25-008182","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VolitionRx Q3 revenue up 32% to $0.6M; signs deals with Werfen and Hologic","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.6M (+32% YoY); net loss down 8% YoY; operating expenses down 10% YoY.","Net cash used in ops $3.6M (-33% YoY); post-quarter raised $6.1M net from public offering.","Signed Research License and Option Agreement for APS with Werfen; Co-Marketing Agreement with Hologic.","In discussions with ~10 leading diagnostic/liquid biopsy companies for further licensing deals.","Anticipates peer-reviewed publications on Nu.Q platform and Capture-Seq technology."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":1280350.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132604,"accession_number":"0001477932-25-008179","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K/A","filed_at":"2025-11-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"VolitionRx amends over-allotment terms; underwriter buys 1.19M shares and 1.73M warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment permits separate exercise of over-allotment shares and warrants, not just combined.","Underwriter exercised over-allotment: 1,194,000 shares at $0.51 and 1,732,500 warrants at $0.01.","Net proceeds to VolitionRx of $582,426 after 7.0% underwriting discount and expenses.","Underwriter also received warrants to buy 83,580 shares at $0.63, exercisable after 6 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132603,"accession_number":"0001477932-25-008019","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K/A","filed_at":"2025-11-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"VolitionRx amends underwriting agreement; over-allotment partially exercised for 1.194M shares and 1.7325M warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment allows Over-Allotment Option to be exercised separately for shares and/or warrants, not combined.","Underwriter exercised Over-Allotment for 1,194,000 shares and 1,732,500 warrants (warrants for 83,580 shares).","Combined offering price was $0.52 per share and $0.01 per warrant; underwriting commission 7.0%.","Original offering closed Oct 10, 2025: 11,550,000 shares and warrants at same terms.","Amendment corrects typographical errors in original Exhibit 1.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132606,"accession_number":"0001477932-25-007984","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"VolitionRx over-allotment exercised: 1.19M shares & 1.73M warrants sold at $0.52/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriter exercised over-allotment option for 1,194,000 shares and 1,732,500 warrants at $0.52 per unit.","Amendment to Underwriting Agreement permits separate exercise of over-allotment for shares and warrants.","Total shares offered increased to 12,744,000; total warrants to 13,282,500.","Gross proceeds from over-allotment approximately $626,325 before 7% underwriting discount."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132605,"accession_number":"0001477932-25-007544","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"VolitionRx raises $6M in underwritten offering; only $0.3M cash pre-offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $6.0M from 11.55M units at $0.52; net ~$5.4M after underwriting discounts and expenses.","Each unit contains one share and one warrant; warrants exercisable at $0.60, 5-year term, cashless basis if no registration.","Pre-offering cash and cash equivalents estimated at only $0.3M as of September 30, 2025.","Offering closed October 14, 2025; directors and officers purchased 254,229 units on same terms.","Proceeds to fund R&D, clinical studies, product commercialization, working capital, and potential strategic acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149136,"accession_number":"0001477932-25-005919","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VolitionRx Q2 2025 revenue ~$0.4M; net loss down 11% YoY; expects first human licensing deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue just over $0.4M; H1 2025 revenue up 15% YoY.","Net loss decreased 11% in Q2 and 24% in H1 vs prior year; operating cash burn down 30% to $10.6M in H1.","Cash & equivalents $2.3M at June 30, 2025; received $1.2M from direct offering post-quarter (director participation).","Management expects first human diagnostics out-licensing deal in Q3 2025; confidential discussions with >10 companies.","Conference call scheduled for August 15, 2025 at 8:30 a.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":653073.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149135,"accession_number":"0001477932-25-005422","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"VolitionRx raises $1.21M in registered direct offering; insiders buy stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["156,250 shares sold to directors/officers at $0.64/share; 1,734,375 shares + warrants at $0.64/unit.","Gross proceeds of $1.21M; potential additional $1.3M from warrants at $0.768/share.","Warrants exercisable for 5 years from Aug 2025; insiders receive no warrants.","No placement agent; offering expected to close Aug 5, 2025.","Net proceeds for R&D, product development, clinical studies, working capital, and potential M&A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168134,"accession_number":"0001477932-25-004721","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"VolitionRx shareholders approve authorized share increase to 325M; all director nominees elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 175M to 325M effective June 18, 2025, via Certificate of Second Amendment.","All eight director nominees elected with ~35-36M votes for each; about 14.7M broker non-votes.","Ratification of Sadler, Gibb & Associates as auditor passed with 51.3M votes for, 330k against.","Non-binding advisory vote on named executive officer compensation passed with 34.4M for, 2.3M against.","Charter amendment proposal passed with 49.5M votes for, 1.8M against, and 385k abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168133,"accession_number":"0001477932-25-003852","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VolitionRx Q1 revenue $0.25M (+44% YoY); first commercial revenue from CE-marked Nu.Q NETs in Europe","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of ~$0.25M in Q1 2025, up 44% from Q1 2024; first revenue from regulated CE-marked Nu.Q NETs automated product.","Net cash used in ops averaged $1.4M/month, down ~50% vs Q1 2024; cash balance $2.6M at March 31, 2025.","Post-quarter closed $6.25M convertible loan note (24-month, 6-month repayment holiday).","Confidential licensing discussions with >10 companies; combined market cap of seven >$600B.","Goal to be cash neutral on full-year 2025 basis via licensing receipts and cost reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":246385.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168132,"accession_number":"0001477932-25-002897","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"VolitionRx enters up to $7.5M at-the-market stock offering agreement with JonesTrading","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New 'Capital on Demand' sales agreement with JonesTrading allows sale of up to $7.5M common stock via ATM.","Sales agent commission 3% of gross proceeds; company not obligated to sell any shares.","Replaces prior $25M ATM program with Jefferies, terminated effective April 20, 2025.","Proceeds intended for R&D, product development, clinical studies, commercialization, working capital, and potential acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168131,"accession_number":"0001477932-25-002475","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"VolitionRx files S-1 to re-register 35.9M warrant shares previously covered by S-3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed new S-1 registration statement to register 35,867,306 shares of common stock issuable upon exercise of previously issued warrants.","These shares were previously registered under a Form S-3 shelf registration (File No. 333-259783) effective Nov 8, 2021.","Company intends to withdraw the old S-3 registration upon SEC effectiveness of the new S-1.","No new shares beyond those previously registered under the S-3 are being registered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185340,"accession_number":"0001477932-25-002227","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VolitionRx reports FY2024 revenue up 59% to $1.2M; cash at $3.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.2M in 2024, up 59% YoY; Nu.Q Vet revenue up 75%, Nu.Q Discover up 40%.","Operating expenses down 23% YoY; post-year-end raised $2.3M equity and $1.8M non-dilutive funding.","Sold ~120,000 Nu.Q Vet Cancer Tests; available in 20+ countries; active commercial discussions for human diagnostics.","Goal to be cash neutral in 2025 via licensing receipts and revenue.","Board strengthened with new Chair Timothy Still and Director Dr. Ethel Rubin."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":246385.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185339,"accession_number":"0001477932-25-002010","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"VolitionRx announces $2.3M registered direct offering; insiders buy 2.36M shares at $0.55","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2,363,636 shares sold to insiders (directors, officers, existing stockholders) at $0.55/share.","1,739,087 shares + warrants (exercise $0.66, 5-year) sold to other investors at $0.55 combined.","Gross proceeds $2.3M upfront; up to $1.1M additional if warrants fully exercised.","Net proceeds for R&D, clinical studies, product commercialization, and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201922,"accession_number":"0001477932-24-007944","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"VolitionRx raises up to $1.9M in registered direct offering with warrants for additional $2.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes 445,648 Insider Shares at $0.5722 and 2,857,389 shares with warrants at $0.5722.","Form A warrants exercisable at $0.5722/share, Form B at $0.71525/share, both expire Dec 2029.","Gross proceeds upfront ~$1.9M; potential additional $2.7M if warrants fully exercised.","Proceeds for R&D, clinical studies, product commercialization, and working capital.","Insiders participate; no placement agent; closing expected on Dec 9, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201921,"accession_number":"0001477932-24-007203","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VolitionRx Q3 revenue $475K, up 187% YoY; sold >110K Nu.Q Vet tests in 9 months","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 revenue $475K, up 187% YoY; YTD revenue $1M, up 96%.","Nu.Q Vet revenue up 307% in Q3; >110,000 tests sold in first 9 months of 2024.","Cash used in operations $5.4M in Q3, down 36% YoY; cash balance $5.4M at Sept 30.","Received >$2.2M in non-dilutive funding commitment from Walloon Region post-quarter.","Reaffirms goal to be cash neutral (income matching expenditure) in 2025."],"consensus_eps_estimate":-0.8976,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":1041854.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201920,"accession_number":"0001477932-24-006916","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"VolitionRx appoints Timothy Still as Chairman, effective November 6, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy Still appointed non-executive Chairman and director of VolitionRx; board expanded to 8 members.","Still has 35+ years in diagnostics, most recently President/CEO of Sense Biodetection (merged with Sherlock).","Compensation includes $30K/quarter retainer, 400K time-vested RSUs, and 1M performance-based RSUs tied to $2.50/$5.00 stock price targets.","Annual RSU grant of 300K shares contingent on corporate goals, subject to share availability under incentive plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217966,"accession_number":"0001477932-24-006038","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"VolitionRx appoints Dr. Ethel Rubin as independent director; board expands to 7","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Rubin appointed effective Sept 30, 2024; board increased from 6 to 7 members.","She will serve on both the Audit Committee and the Compensation Committee.","Compensation: $10,840 per quarter plus 15,000 RSUs vesting over 3 years.","Dr. Rubin brings 20+ years life sciences experience; previously at Medtronic and BioHealth Innovation.","She contributed to over 25 commercial products and multiple M&A, partnerships."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217965,"accession_number":"0001477932-24-005988","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"VolitionRx enters CEO employment agreement with Dr. Michel for Belgian subsidiary; consulting fee amended","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Employment agreement with Dr. Gaetan Michel as CEO of Belgian Volition, effective Sept 1, 2024, with €12,000/month salary plus 13th month bonus.","Consulting agreement amendment with 3F Management SRL increases monthly fee to €15,598 from Nov 1, 2024; variable bonus up to €26,390.","Dr. Michel also serves as COO of parent, CEO of Volition America, and Manager of Volition Veterinary Diagnostics.","Combined aggregate annual compensation is materially consistent with prior arrangements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217964,"accession_number":"0001477932-24-005745","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"VolitionRx markets oncology portfolio for out-licensing via PharmaVentures","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company engaged PharmaVentures as licensing adviser; document made available to third parties starting September 16, 2024.","Document provides brief introduction to certain components of the oncology portfolio; no specific assets or terms disclosed.","No revenue, deal value, or counterparty announced; no financial impact provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217963,"accession_number":"0001477932-24-004835","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VolitionRx Q2 revenue up 83% to $396K; H1 test sales exceed full-year 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $396K (+83% YoY); H1 revenue $567K (+55% YoY).","Operating expenses down 24% YoY in Q2; targeting $10M annualized cost reductions.","Cash $6.0M at June 30; closed $7M registered direct offering with up to $14.5M in milestone-linked warrants.","Sold over 60,000 Nu.Q Vet Cancer Tests in H1 2024 (vs 58,000 full-year 2023); now available in 17 countries.","Engaged PharmaVentures to advise on licensing deals for Nu.Q Cancer and Capture-PCR."],"consensus_eps_estimate":-1.02,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":567332.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217962,"accession_number":"0001477932-24-004671","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"VolitionRx raises $7M in registered direct offering with milestone-linked warrants for up to $14.5M additional","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$7M from sale of 12.7M shares/pre-funded warrants at $0.55 each; warrants exercisable at $0.57.","Series A warrants expire 60 days after announcement of $10M+ milestone commercial agreements; series B expire 6 months after first FDA approval.","Potential additional $14.5M if all milestone-linked warrants exercised on cash basis; no assurance of exercise.","Net proceeds earmarked for R&D, clinical studies, product commercialization, working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217961,"accession_number":"0001477932-24-004059","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"VolitionRx shareholders approve 75% increase in authorized shares to 175M and new equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized shares increased from 100M to 175M (75% increase), effective July 2, 2024 via Certificate of Amendment.","2024 Stock Incentive Plan adopted, reserving 7.5M shares for future equity awards to employees, directors, and consultants.","Six director nominees elected; auditor Sadler, Gibb & Associates ratified; say-on-pay advisory vote passed.","All five stockholder proposals at annual meeting passed; 49.0M of 82.8M shares outstanding were voted.","Both the share increase and equity plan were stockholder-approved and immediately effective."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237897,"accession_number":"0001477932-24-003896","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"VolitionRx mid-year: Vet test in 15 countries, $23M milestones, human license target H2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nu.Q Vet Cancer Test now available in 15 countries via Antech, IDEXX, Fujifilm; aiming to triple 2023 test sales of 58,000.","Received $23M in upfront and milestone payments from Heska (Antech) for veterinary test.","Preparing data rooms for Nu.Q NETs, Nu.Q Lung, and Capture-PCR technologies; first human licensing deal targeted in H2 2024.","Capture-PCR method for direct ctDNA detection submitted for peer review July 2024; early-stage cancer discrimination demonstrated.","Active commercial discussions with major liquid biopsy, IVD, and oncology players."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237896,"accession_number":"0001477932-24-002772","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VolitionRx Q1 revenue $170k (+15% YoY); cash $11.8M; targets $10M annual cost cuts for 2025 cash flow neutrality","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue ~$170,000, up 15% YoY; cash and equivalents $11.8M as of March 31, 2024.","Targeting $10M in annualized cost reductions; aiming for cash flow neutrality in 2025 via non-dilutive funding, revenue growth, and milestone payments.","Applied for $25M in U.S. and $18M in European non-dilutive grants.","Expects substantial Nu.Q NETs and Capture-PCR clinical data by end of June; then laser focus on commercialization.","Volition Vet revenue expected to accelerate in H2 2024 after recent Antech and Fujifilm product launches."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":171535.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237895,"accession_number":"0001477932-24-002348","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"VolitionRx board shrinks from 8 to 6; two long-serving directors retire; quorum lowered to 33%","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Executive Chairman Faulkes and director Futcher to retire after 12 & 7 years, not standing for re-election at July 2, 2024 meeting.","Board size reduced from 8 to 6 immediately prior to the Annual Meeting; Guy Innes named interim Chairman and Nominations Chair.","Faulkes will remain as employee for 3 months post-meeting to assist with transition; retirements not due to any dispute.","Bylaws amended to lower stockholder quorum requirement from majority to 33 1/3% of voting power for all meetings.","Six directors to be nominated for re-election at the Annual Meeting; board expects election of nominees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255382,"accession_number":"0001477932-24-001451","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VolitionRx reports FY2023 revenue up 153% to $775K; cash $20.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of ~$775K in FY2023, up 153% YoY; net cash used in operations $18.1M.","Cash & equivalents $20.7M at Dec 31, 2023 (vs $10.9M end of 2022); received $13.0M milestone from Heska in Dec 2023.","Sold kits for over 58,000 Nu.Q Vet Cancer Tests in 2023; new partnerships including Fujifilm Vet Systems; in-house test via Heska/Antech coming soon.","Nu.Q NETs pillar advanced with FDA regulatory pathway; Capture-PCR breakthrough presented at ESMO 2023.","Conference call March 26, 2024 at 8:30 AM ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255381,"accession_number":"0001477932-24-001328","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"VolitionRx appoints Dr. Andrew Retter as Chief Medical Officer effective April 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Retter is an Intensive Care Consultant at Guy's and St. Thomas' NHS Foundation Trust, London, and dual-registered in Intensive Care and Haematology.","He has advised Volition since January 2022 on Nu.Q® NETs, a CE-marked blood test for sepsis and NETosis-related diseases.","As CMO, he will lead medical strategy and ensure clinical efforts are aligned with patient needs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255380,"accession_number":"0001477932-24-000002","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2024-01-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"VolitionRx receives $13.0M milestone from Heska for Nu.Q Vet Cancer Test transfer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $13.0 million in milestone payments from Heska Corporation.","Milestone triggered by successful assay transfer of Nu.Q Vet Cancer Test onto Heska's Element i+ point-of-care platform.","Payment stems from March 2022 License and Supply Agreement between Belgian Volition SRL and Heska.","Test is marketed as the 'Heska Nu.Q Vet Canine Cancer Screen and Monitor.'"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272855,"accession_number":"0001477932-23-008963","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2023-12-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"VolitionRx secures ~$5.5M financing from Belgian regional government WE","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total financing €5.0M (~$5.5M) from Wallonie Entreprendre; €2.5M unsecured loan at 8% interest, maturity Dec 2028.","€2.5M equity component: WE purchases 3,205,431 restricted shares at $0.8337 per share.","Proceeds for Nu.Q product development, including Nu.Q NETs sepsis diagnostic clinical program.","Loan drawable in three tranches: €1.5M immediate, €0.5M from June 2024, €0.5M from March 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272854,"accession_number":"0001477932-23-008448","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VolitionRx reports 185% revenue increase in 9M 2023; FDA 510(k) pathway for NETs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue for first nine months 2023 was $531k, up 185% YoY; Nu.Q Vet Cancer Test revenue grew ~5x.","Cash and equivalents $10.8M as of Sep 30, 2023, roughly flat vs year-end 2022.","Post-quarter: Walloon funding approved for ~$6M; expects $13M milestone payments from Heska.","FDA agreed to traditional 510(k) pathway for Nu.Q NETs test following Q-Sub process.","Launched Nu.Q Vet Test in UK/Ireland via NationWide Laboratories and Veterinary Pathology Group."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":531329.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289693,"accession_number":"0001477932-23-006099","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VolitionRx submits Breakthrough Device request to FDA for Nu.Q sepsis test; H1 revenue exceeds full-year 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Submitted Breakthrough Device Designation Request to FDA for Nu.Q technology in sepsis in June 2023.","H1 2023 total revenue $366,000, exceeding full-year 2022 revenue; Nu.Q Vet sales grew five-fold.","Cash $19.7M at June 30, 2023, vs $10.9M at 2022 year-end; raised $17.6M net in June public offering.","Expects $13M in milestone payments from Heska and additional non-dilutive Belgian agency funding.","Centers of Excellence for Nu.Q NETs progressing; first clinical paper submitted for peer review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":366118.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310566,"accession_number":"0001477932-23-004956","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"VolitionRx stockholders approve 1.95M share increase in 2015 Stock Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders voted to amend the 2015 Stock Incentive Plan, increasing available shares by 1,950,000 to 9,700,000.","All eight director nominees elected: Barnes, Colman, Faulkes, Futcher, Henshall, Innes, Nguyen, Reynolds.","Ratification of auditor Sadler, Gibb & Associates passed with 41.8M for vs 631K against.","Advisory vote on executive compensation approved (16.7M for, 13.5M against).","Annual meeting initially adjourned on June 23 due to lack of quorum; reconvened June 28 with quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310565,"accession_number":"0001477932-23-004228","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2023-06-05T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"VolitionRx prices $16.5M public offering of 13M shares at $1.27 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $16.5M from 13M shares at $1.27/share; net proceeds ~$15.4M.","Underwriters granted 30-day option to buy up to 1.95M additional shares at same price.","Net proceeds for R&D, clinical studies, commercialization, working capital, and possible M&A.","Underwriter warrants issued to buy up to 448,500 shares at $2.00/share, exercisable after 6 months.","Offering expected to close on June 5, 2023, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310564,"accession_number":"0001477932-23-003238","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VolitionRx Q1 sales jump 381% to $124k; cash $10M; expects $13M milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Nu.Q Vet Cancer Test sales rose 381% YoY to $124,000 in Q1 2023.","Cash and equivalents $10.0M at March 31, 2023 vs $10.9M at year-end 2022.","Received ~$8M net from Feb public offering; expects $13M in Heska milestone payments and additional non-dilutive Belgian funding.","Launched Nu.Q Vet Cancer Test through IDEXX and Heska; planning more country launches in 2023.","Advancing Nu.Q NETs test for sepsis with multi-site U.S. studies and FDA Breakthrough Device application."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":149808.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329208,"accession_number":"0001477932-23-001496","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VolitionRx FY22 revenue $300k, cash $10.9M; Heska deal advances with $10M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.3M, up 240% YoY; net cash used in operations $15.3M ($1.3M/month).","Cash & equivalents $10.9M at Dec 31, 2022; raised ~$8.0M net in Feb 2023 offering.","Heska agreement: $10M upfront received, up to $18M milestones; IDEXX launched Nu.Q Vet test.","Nu.Q NETs CE marked; FDA Breakthrough Device application expected H1 2023.","34 patent families, 97 granted patents; capital market day set for May 11, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329207,"accession_number":"0001477932-23-001176","cik":93314,"company_name":"VOLITIONRX LTD","ticker":"VNRX","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["1.01","2.02","8.01","9.01"],"status":"ready","headline":"VolitionRx raises $7.525M in public offering of 4.3M shares plus full over-allotment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $7.525M from 4,300,000 shares at $1.75/share; net ~$8.0M after underwriting discount.","Underwriter exercised option for 645,000 additional shares, bringing total to 4,945,000 shares.","Proceeds to fund R&D, clinical studies, product commercialization, working capital, and potential acquisitions.","Preliminary unaudited cash and equivalents of ~$10.9M as of Dec 31, 2022.","Offering led by Newbridge Securities; closed Feb 22, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":19580000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-02-21T23:59:59+00:00|329207"}